Actuate Therapeutics (NASDAQ:ACTU) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Actuate Therapeutics (NASDAQ:ACTU) issued its earnings results on Thursday. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02, Zacks reports.

Actuate Therapeutics Stock Performance

NASDAQ ACTU opened at $5.91 on Friday. The stock has a market cap of $137.35 million, a P/E ratio of -5.05 and a beta of -0.23. Actuate Therapeutics has a fifty-two week low of $5.47 and a fifty-two week high of $11.99. The stock has a 50 day simple moving average of $6.97 and a two-hundred day simple moving average of $7.76.

Institutional Trading of Actuate Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE lifted its stake in shares of Actuate Therapeutics by 61,068.0% in the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after purchasing an additional 15,267 shares during the period. New York State Common Retirement Fund bought a new position in Actuate Therapeutics in the second quarter worth $105,000. Northwestern Mutual Wealth Management Co. lifted its position in Actuate Therapeutics by 492.6% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company’s stock valued at $113,000 after buying an additional 15,393 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Actuate Therapeutics by 98.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company’s stock valued at $151,000 after buying an additional 11,105 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Actuate Therapeutics by 252.5% in the 2nd quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock worth $721,000 after buying an additional 84,561 shares during the period.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ACTU shares. B. Riley began coverage on Actuate Therapeutics in a report on Tuesday, August 26th. They issued a “buy” rating and a $20.00 price objective on the stock. Wall Street Zen raised Actuate Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Thursday. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Actuate Therapeutics in a report on Tuesday, September 23rd. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $20.33.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.